Han Erica, Burdsall Kaitlyn, Escamilla Oshea
Hematology, Edward Via College of Osteopathic Medicine, Spartanburg, USA.
Family Medicine, Edward Via College of Osteopathic Medicine, Spartanburg, USA.
Cureus. 2024 Jul 2;16(7):e63701. doi: 10.7759/cureus.63701. eCollection 2024 Jul.
Factor V Leiden (FVL) is a hypercoagulable disorder that puts patients at increased risk of initial venous thromboembolism (VTE). However, those with heterozygote status are not usually susceptible to recurrent VTE. This is a case of a 35-year-old Caucasian male who presented to the emergency department with shortness of breath and chest pain. He had a past medical history of superficial thrombophlebitis and deep vein thrombosis (DVT) and was known to be FVL heterozygous. His home medications did not include anticoagulation medications at the time of presentation to the emergency department. The patient was diagnosed with bilateral pulmonary embolisms (PEs) secondary to a recurrent DVT. Initial treatment included a pulmonary thrombectomy and a lower extremity thrombectomy. Despite the patient being placed on heparin, there was a recurrence of the PE three days later, requiring a repeat pulmonary thrombectomy. This case of recurrent VTE in a heterozygous FVL patient is unusual and should lead to new considerations on the approach to lifelong anticoagulation in these patients.
因子V莱顿突变(FVL)是一种高凝性疾病,会使患者发生初始静脉血栓栓塞(VTE)的风险增加。然而,杂合子状态的患者通常不易发生复发性VTE。这是一名35岁的白种男性病例,他因呼吸急促和胸痛就诊于急诊科。他既往有浅表血栓性静脉炎和深静脉血栓形成(DVT)病史,已知为FVL杂合子。在他就诊于急诊科时,其家庭用药中不包括抗凝药物。该患者被诊断为复发性DVT继发双侧肺栓塞(PE)。初始治疗包括肺血栓切除术和下肢血栓切除术。尽管患者接受了肝素治疗,但三天后PE复发,需要再次进行肺血栓切除术。这名FVL杂合子患者出现复发性VTE的病例并不常见,应促使人们对这些患者的终身抗凝治疗方法进行新的思考。